UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000056749
Receipt number R000064853
Scientific Title Treatment status and clinical symptoms in patients with chronic hypoparathyroidism: a retrospective cross-sectional study using real-world data
Date of disclosure of the study information 2025/01/17
Last modified on 2025/01/17 19:04:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Database study on treatment status and clinical symptoms in patients with chronic hypoparathyroidism

Acronym

Database study on treatment status and clinical symptoms in patients with chronic hypoparathyroidism

Scientific Title

Treatment status and clinical symptoms in patients with chronic hypoparathyroidism: a retrospective cross-sectional study using real-world data

Scientific Title:Acronym

Treatment status and clinical symptoms in patients with chronic hypoparathyroidism: a retrospective cross-sectional study using real-world data

Region

Japan


Condition

Condition

hypoparathyroidism

Classification by specialty

Endocrinology and Metabolism Nephrology Endocrine surgery
Pediatrics Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate treatment status and clinical symptoms among patients with chronic hypoparathyroidism in actual clinical settings using real-world data.

Basic objectives2

Others

Basic objectives -Others

Actual clinical practice

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

(1) Patient characteristics (patient demographics, laboratory test results, and comorbidities)
(2) Treatment status (actual status of prescriptions under conventional therapy, and status of serum calcium level control under that therapy)
(3) Clinical symptoms

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who met the criteria for hypoparathyroidism and were prescribed conventional drug regimen between 180 and 300 days after meeting those criteria, from January 1, 2016 to June 30, 2024.

Key exclusion criteria

Not applicable

Target sample size

2000


Research contact person

Name of lead principal investigator

1st name Hiroyuki
Middle name
Last name Sugiyama

Organization

Teijin Pharma Limited

Division name

Medical Science Department

Zip code

100-8585

Address

2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo

TEL

03-3506-4140

Email

tpm-com@umin.ac.jp


Public contact

Name of contact person

1st name Mana
Middle name
Last name Kujirai

Organization

Teijin Pharma Limited

Division name

Medical Science Department

Zip code

100-8585

Address

2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo

TEL

03-3506-4140

Homepage URL


Email

tpm-com@umin.ac.jp


Sponsor or person

Institute

Teijin Pharma Limited

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Teijin Pharma Limited

Address

2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo

Tel

03-3506-4140

Email

tpm-com@umin.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 01 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 01 Month 10 Day

Date of IRB


Anticipated trial start date

2025 Year 01 Month 20 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a cross-sectional study using Millennial Medical Record offered by Life Data Initiative, General Incorporated Association.


Management information

Registered date

2025 Year 01 Month 17 Day

Last modified on

2025 Year 01 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064853